Literature DB >> 23537574

Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.

Korbinian Löbmann1, Holger Grohganz, Riikka Laitinen, Clare Strachan, Thomas Rades.   

Abstract

Poor aqueous solubility of an active pharmaceutical ingredient (API) is one of the most pressing problems in pharmaceutical research and development because up to 90% of new API candidates under development are poorly water soluble. These drugs usually have a low and variable oral bioavailability, and therefore an unsatisfactory therapeutic effect. One of the most promising approaches to increase dissolution rate and solubility of these drugs is the conversion of a crystalline form of the drug into its respective amorphous form, usually by incorporation into hydrophilic polymers, forming glass solutions. However, this strategy only led to a small number of marketed products usually because of inadequate physical stability of the drug (crystallization). In this study, we investigated a fundamentally different approach to stabilize the amorphous form of drugs, namely the use of amino acids as small molecular weight excipients that form specific molecular interactions with the drug resulting in co-amorphous forms. The two poorly water soluble drugs carbamazepine and indomethacin were combined with amino acids from the binding sites of the biological receptors of these drugs. Mixtures of drug and the amino acids arginine, phenylalanine, tryptophan and tyrosine were prepared by vibrational ball milling. Solid-state characterization with X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) revealed that the various blends could be prepared as homogeneous, single phase co-amorphous formulations indicated by the appearance of an amorphous halo in the XRPD diffractograms and a single glass transition temperature (Tg) in the DSC measurements. In addition, the Tgs of the co-amorphous mixtures were significantly increased over those of the individual drugs. The drugs remained chemically stable during the milling process and the co-amorphous formulations were generally physically stable over at least 6 months at 40 °C under dry conditions. The dissolution rate of all co-amorphous drug-amino acid mixtures was significantly increased over that of the respective crystalline and amorphous pure drugs. Amino acids thus appear as promising excipients to solve challenges connected with the stability and dissolution of amorphous drugs.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amino acids; Co-amorphous; Dissolution; Drug; Glass transition temperature; Small molecular excipients; Stability

Mesh:

Substances:

Year:  2013        PMID: 23537574     DOI: 10.1016/j.ejpb.2013.03.014

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  22 in total

1.  Investigating Cocrystallization of Carbamazepine with Structurally Compatible Coformers: New Cocrystal and Eutectic Phases with Enhanced Dissolution.

Authors:  Indumathi Sathisaran; Sameer Vishvanath Dalvi
Journal:  AAPS PharmSciTech       Date:  2021-01-06       Impact factor: 3.246

2.  New Perspectives for Fixed Dose Combinations of Poorly Water-Soluble Compounds: a Case Study with Ezetimibe and Lovastatin.

Authors:  Manoela K Riekes; Axel Engelen; Bernard Appeltans; Patrick Rombaut; Hellen K Stulzer; Guy Van den Mooter
Journal:  Pharm Res       Date:  2016-02-08       Impact factor: 4.200

3.  Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.

Authors:  Sharad Mangal; Haichen Nie; Rongkun Xu; Rui Guo; Alex Cavallaro; Dmitry Zemlyanov; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-01-08       Impact factor: 4.200

4.  A Strategy for Co-former Selection to Design Stable Co-amorphous Formations Based on Physicochemical Properties of Non-steroidal Inflammatory Drugs.

Authors:  Hiroshi Ueda; Noriyuki Muranushi; Satoshi Sakuma; Yasuo Ida; Takeshi Endoh; Kazunori Kadota; Yuichi Tozuka
Journal:  Pharm Res       Date:  2015-12-24       Impact factor: 4.200

Review 5.  Drug-Rich Phases Induced by Amorphous Solid Dispersion: Arbitrary or Intentional Goal in Oral Drug Delivery?

Authors:  Kaijie Qian; Lorenzo Stella; David S Jones; Gavin P Andrews; Huachuan Du; Yiwei Tian
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

6.  Pharmaceutical Co-Crystals, Salts, and Co-Amorphous Systems: A Novel Opportunity of Hot Melt Extrusion.

Authors:  Sagar Narala; Dinesh Nyavanandi; Priyanka Srinivasan; Preethi Mandati; Suresh Bandari; Michael A Repka
Journal:  J Drug Deliv Sci Technol       Date:  2020-11-09       Impact factor: 3.981

7.  A novel drug-drug coamorphous system without molecular interactions: improve the physicochemical properties of tadalafil and repaglinide.

Authors:  Meiling Su; Yanming Xia; Yajing Shen; Weili Heng; Yuanfeng Wei; Linghe Zhang; Yuan Gao; Jianjun Zhang; Shuai Qian
Journal:  RSC Adv       Date:  2020-01-02       Impact factor: 4.036

8.  Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline.

Authors:  Katrine Tarp Jensen; Korbinian Löbmann; Thomas Rades; Holger Grohganz
Journal:  Pharmaceutics       Date:  2014-07-14       Impact factor: 6.321

Review 9.  Amino Acids as the Potential Co-Former for Co-Crystal Development: A Review.

Authors:  Ilma Nugrahani; Maria Anabella Jessica
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

10.  Influence of Solvent Composition on the Performance of Spray-Dried Co-Amorphous Formulations.

Authors:  Jaya Mishra; Thomas Rades; Korbinian Löbmann; Holger Grohganz
Journal:  Pharmaceutics       Date:  2018-04-12       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.